Page 89 - Haematologica-April 2018

Correlation of mutations with morphological findings in AML
With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017;35(14):1598-1605.
17. Weinberg OK, Gibson CJ, Blonquist TM, et al. NPM1 mutation but not RUNX1 muta- tion or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytoge- netic abnormalities in the revised 2016 WHO classification. Am J Hematol. 2017;92(7):E123-E124.
18. Kluk MJ, Lindsley RC, Aster JC, et al. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. J Mol Diagn. 2016;18(4):507- 515.
19. Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016;128(9):1246-1259.
20. Thol F, Bollin R, Gehlhaar M, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood. 2014;123(6):914-920.
21. Mullenders J, Aranda-Orgilles B, Lhoumaud P, et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, lead- ing to myeloproliferative neoplasms. J Exp Med. 2015;212(11):1833-1850.
22. Li Z, Zhang P, Yan A, et al. ASXL1 inter- acts with the cohesin complex to maintain chromatid separation and gene expression
for normal hematopoiesis. Sci Adv.
2017;3(1):e1601602.
23. Cho YU, Jang S, Seo EJ, et al. Preferential
occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology. Leuk Lymphoma. 2015;56(8):2301-2308.
24. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-2221.
25. Feng G, Gale RP, Cui W, et al. A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol 2016;5:12.
haematologica | 2018; 103(4)
633